A new Cleveland Clinic-led study published in The EMBO Journal shows that mild and asymptomatic SARS-CoV-2 infections can trigger immune responses in a pregnant individual that may cause serious inflammatory responses in the developing fetus.
FDA allows first pivotal trial of an in vivo gene editing treatment from Intellia
The FDA cleared Intellia Therapeutics to run a Phase III study of its CRISPR-based therapy for transthyretin (ATTR) amyloidosis with cardiomyopathy, paving the way for
October 19, 2023